메뉴 건너뛰기




Volumn 1, Issue 2, 2015, Pages 141-142

The cost and value of anti-epidermal growth factor receptor therapies: Let's not be rash

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN P21;

EID: 84965092815     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.0287     Document Type: Short Survey
Times cited : (3)

References (6)
  • 1
    • 84907027361 scopus 로고    scopus 로고
    • CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
    • s; ASCO annual meeting
    • Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32(5s):suppl; abstr LBA3, ASCO annual meeting.
    • (2014) J Clin Oncol , vol.32 , Issue.5
    • Venook, A.P.1    Niedzwiecki, D.2    Lenz, H.-J.3
  • 2
    • 84908573757 scopus 로고    scopus 로고
    • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial
    • Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065-1075.
    • (2014) Lancet Oncol , vol.15 , Issue.10 , pp. 1065-1075
    • Heinemann, V.1    Von Weikersthal, L.F.2    Decker, T.3
  • 3
    • 84937204003 scopus 로고    scopus 로고
    • CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC)
    • Proc European Society of Medical Oncology
    • Lenz H-J, Niedzwiecki D, Innocenti F, et al. CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Oncol. 2014;25(suppl 5):v1-v41; abstr 501O, Proc European Society of Medical Oncology.
    • (2014) Ann Oncol , vol.25 , pp. v1-v41
    • Lenz, H.-J.1    Niedzwiecki, D.2    Innocenti, F.3
  • 4
    • 54949085398 scopus 로고    scopus 로고
    • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    • Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-1765.
    • (2008) N Engl J Med , vol.359 , Issue.17 , pp. 1757-1765
    • Karapetis, C.S.1    Khambata-Ford, S.2    Jonker, D.J.3
  • 5
    • 84883680951 scopus 로고    scopus 로고
    • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
    • Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023-1034.
    • (2013) N Engl J Med , vol.369 , Issue.11 , pp. 1023-1034
    • Douillard, J.-Y.1    Oliner, K.S.2    Siena, S.3
  • 6
    • 84905870196 scopus 로고    scopus 로고
    • PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer
    • Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240-2247.
    • (2014) J Clin Oncol , vol.32 , Issue.21 , pp. 2240-2247
    • Schwartzberg, L.S.1    Rivera, F.2    Karthaus, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.